Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...
The upcoming patent expiry for Ozempic in India is set to dramatically lower the cost of semaglutide, making this once-premium diabetes and weight-loss drug accessible to more patients. This shift ...
Feb 25 - Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in late March, it said on ...
Ahmedabad: Zydus Lifesciences Limited said it plans to launch semaglutide injection in India under the brand names Semaglyn, Mashema and Alterme after.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results